Log in to search using one of your social media accounts:

 

New combination drug controls tumor growth and metastasis in mice
(University of California - Davis Health System) Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase inhibitor, the drug controls angiogenesis, limiting a tumor's ability to grow and spread. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2014 Category: Global & Universal Source Type: news

Celecoxib May Reduce Pain After Face-liftCelecoxib May Reduce Pain After Face-lift
The COX-2 inhibitor does not have the considerable adverse effects of opioids, but the cost is high, and insurance may not cover it. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2014 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine News Source Type: news

First Generic Versions Of Pfizer's Celebrex Approved By The FDA
The U.S. Food and Drug Administration (FDA) announced that it has granted approval to Teva and Mylan’s generic versions of Pfizer’s Celebrex (celecoxib). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - June 3, 2014 Category: Pharmaceuticals Source Type: news

FDA Approves First Generic Versions of Celecoxib
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 2, 2014 Category: Journals (General) Source Type: news

FDA Approves Generic Version of Painkiller Celebrex
Title: FDA Approves Generic Version of Painkiller CelebrexCategory: Health NewsCreated: 5/30/2014 4:36:00 PMLast Editorial Review: 6/2/2014 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 2, 2014 Category: Rheumatology Source Type: news

FDA Approves Generic Celecoxib (FREE)
By the Editors The FDA has … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 2, 2014 Category: Primary Care Source Type: news

Generic Celebrex (celecoxib) Gets FDA OkayGeneric Celebrex (celecoxib) Gets FDA Okay
Teva Pharmaceutical Industries will market capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg. Mylan Pharmaceuticals received approval to market a 50-mg capsule. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 31, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Business Briefing: F.D.A. Approves Celebrex in Generic Versions
The blockbuster drug, known generically as celecoxib, is used to treat pain, rheumatoid arthritis, osteoarthritis and other conditions. (Source: NYT Health)
Source: NYT Health - May 30, 2014 Category: Consumer Health News Authors: By THE ASSOCIATED PRESS Tags: Celebrex (Drug) Pfizer Inc PFE NYSE Food and Drug Administration Generic Brands and Products Mylan Inc MYL NASDAQ Source Type: news

Generic Celecoxib Gets FDA Nod
(MedPage Today) -- The FDA has approved generic versions of the COX-2 selective nonsteroidal anti-inflammatory drug celecoxib, the agency announced today. (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - May 30, 2014 Category: Anesthesiology Source Type: news

FDA Approves Generic Version of Painkiller Celebrex
Medicine will carry warning alerting users of potential heart risks (Source: WebMD Health)
Source: WebMD Health - May 30, 2014 Category: Consumer Health News Source Type: news

FDA approves first generic versions of celecoxib
The U.S. Food and Drug Administration today approved the first generic versions of Celebrex (celecoxib) capsules, a treatment for rheumatoid arthritis, osteoarthritis, short-term (acute) pain, and other conditions. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 30, 2014 Category: American Health Source Type: news

Celebrex cost high in United States, low in Canada
Read the full story on MD Consult: Celebrex cost high in United States, low in Canada (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - May 14, 2014 Category: Journals (General) Source Type: news

FyMed Announces Top-Line Results Demonstrating Superiority of FY103B...
FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety.(PRWeb April 24, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11785126.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 25, 2014 Category: Pharmaceuticals Source Type: news

Pfizer To Appeal Court Decision On Celebrex Reissue Patent
Pfizer Inc. announced it will appeal the court decision regarding blockbuster painkiller Celebrex reissue patent. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 13, 2014 Category: Pharmaceuticals Source Type: news

U.S. Court Cuts 18 Months Off Pfizer Celebrex Patent Life
Federal court has invalidated a patent that would have offered Pfizer an additional 18 months of U.S. exclusivity for its blockbuster painkiller, Celebrex. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 13, 2014 Category: Pharmaceuticals Source Type: news

Pfizer Says Court Invalidates Celebrex Patent
Pfizer said a federal court has invalidated a reissue patent that would have offered an additional 18 months of U.S. exclusivity — and monopoly sales — to its blockbuster painkiller Celebrex. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 13, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Here's How Big Pfizer Is
Earlier today Pfizer stock was halted by the New York Stock Exchange. The reason: A Virginia court had invalidated the patent on the company's drug Celebrex, which is expected to generate $2.1 billion in annual sales in 2014. In the worst case, generics of Celebrex could be available starting May 30, says Mark Schoenebaum at ISI Group, dropping earnings per share by $0.12 cents. Which sounds disastrous. Celebrex was supposed to last until early 2016, meaning that Pfizer is losing about $3 billion in revenues. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 12, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Pfizer says U.S. court invalidates Celebrex patent; generics loom
(Reuters) - A U.S. court ruled invalid a patent covering Pfizer Inc's blockbuster Celebrex painkiller, the drugmaker said, giving generic rivals an earlier U.S. entry that analysts estimated could cost the company $3 billion in revenue by the end of 2015. (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

How Common is Hypersensitivity Cross-Reactivity with NSAIDs?
In this study, acetaminophen did not show cross-reactivity which is different than other studies that have shown ~25% cross-reactivity. The authors note that they did challenge testing which is different than many studies that use clinical history as the defining element of cross-reactivity. Questions for Further Discussion 1. What is the definition of angioedema? 2. What evaluation should be considered for a patient with potential NSAID hypersensitivity reaction? 3. What treatment options are available for pain and fever relief for patients with an NSAID hypersensitivity reaction? Related Cases Disease: Drug Reaction | St...
Source: PediatricEducation.org - February 17, 2014 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Pre-operative Celecoxib Treatment in Primary Breast CancerPre-operative Celecoxib Treatment in Primary Breast Cancer
Learn more about the effect of COX-2 inhibition in primary breast cancer and whether it should be further considered as a treatment option. Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Investigational submicron diclofenac reduces use of opioid rescue medication in post-surgical pain in a Phase 3 study
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, has announced that the company's investigational, non-steroidal anti-inflammatory drug (NSAID) submicron diclofenac reduced the use of opioid rescue medication in patients with acute pain following bunionectomy surgery. Specifically, the study showed that significantly fewer patients who received submicron particle diclofenac capsules 35 mg (82 percent; P = 0.002) or 18 mg (85 percent; P = 0.005), or who received active comparator celecoxib (85 percent; P = 0... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 9, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

High-dose painkiller heart risk: small but significant
Conclusion This large review adds to, and expands on, the current evidence on the risks of vascular disease and gastrointestinal complications for different NSAIDs. It largely concentrates on trials of high doses of NSAIDs that can only be prescribed by a doctor. It is unclear from this study whether there is any risk from taking lower doses available over the counter. While most experts advise that low-dose NSAIDs, taken occasionally, are safe for most people, an accompanying editorial points out that there are still “large gaps” in evidence on the risks with lower doses of NSAIDs. While the risk to individual...
Source: NHS News Feed - May 30, 2013 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Pfizer Celecoxib meets primary endpoint in Phase IV juvenile idiopathic arthritis trial
Pfizer Celecoxib has met its primary endpoint in a Phase IV trial evaluating its effects on blood pressure in paediatric patients with juvenile idiopathic arthritis (JIA). (Source: Drug Development Technology)
Source: Drug Development Technology - April 28, 2013 Category: Pharmaceuticals Source Type: news

Some Pain Drugs Increase the Risk of Heart Attack
ROCHESTER, Minn. — Some of the most common pain drugs used by older adults who experience discomfort in muscles and joints can increase the risk of heart attack and stroke. The April issue of Mayo Clinic Health Letter covers the risks of nonsteroidal anti-inflammatory drugs (NSAIDs) that include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Advil, Motrin [...] (Source: Mayo Clinic Health Information)
Source: Mayo Clinic Health Information - April 26, 2013 Category: Consumer Health News Source Type: news

Pfizer fails to end lawsuit over Bextra, Celebrex safety
(Reuters) - Pfizer Inc has failed to persuade a federal judge to dismiss a shareholder lawsuit accusing the company of fraudulently misrepresenting the safety of its Celebrex and Bextra pain-relieving drugs. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer Painkiller Gets Longer Patent Protection
Pfizer could gain an additional 18 months of U.S. exclusivity—and monopoly sales—for its painkiller Celebrex because the government effectively reinstated a patent whose claims were previously struck down in court. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 6, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news